3.94

0.77% +0.03

After Hours: 3.9981 0.0581 +1.47%

Aldeyra Therapeutics Inc (ALDX)

Overview News Price History Option Chain Discussions Forecast

Aldeyra Therapeutics Inc stock is currently priced at $3.94, with a 24-hour trading volume of 564.94K. It has seen a +0.77% increased in the last 24 hours and a +35.86% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.99 pivot point. If it approaches the $3.81 support level, significant changes may occur.

Previous Close:

$3.91

Open:

$3.94

24h Volume:

564.94K

Market Cap:

$234.09M

Revenue:

Net Income/Loss:

$-37.54M

P/E Ratio:

-4.427

EPS:

-0.89

Net Cash Flow:

$-30.33M

1W Performance:

-0.76%

1M Performance:

+35.86%

6M Performance:

+147.80%

1Y Performance:

-58.31%

1D Range:

$3.875

$4.00

52W Range:

$1.42

$11.97

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name

Aldeyra Therapeutics Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

781-761-4904

Address

131 Hartwell Avenue, Suite 320, Lexington, MA

Employee

Twitter

@aldeyraaldx

Next Earnings Date

2024-05-02

Latest SEC Filings

ALDX's Discussions on Twitter

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-22	Resumed	H.C. Wainwright	Buy
Feb-08-21	Initiated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Oct-30-20	Initiated	Jefferies	Buy
Oct-16-20	Initiated	BTIG Research	Buy
Sep-22-20	Initiated	Alliance Global Partners	Buy
May-12-20	Initiated	Oppenheimer	Outperform
Dec-04-18	Initiated	Citigroup	Buy
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy
Sep-26-16	Initiated	H.C. Wainwright	Buy
Jul-01-16	Initiated	Stifel	Buy
Jul-01-15	Initiated	Canaccord Genuity	Buy
Mar-25-15	Initiated	Chardan Capital Markets	Buy
Mar-20-15	Reiterated	H.C. Wainwright	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy
Jun-19-14	Initiated	Aegis Capital	Buy

View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

Aldeyra Therapeutics Inc Stock (ALDX) Financials Data

Aldeyra Therapeutics Inc (ALDX) Net Income 2024

ALDX net income (TTM) was -$37.54 million for the quarter ending December 31, 2023, a +39.47% increase year-over-year.

Aldeyra Therapeutics Inc (ALDX) Cash Flow 2024

ALDX recorded a free cash flow (TTM) of -$30.33 million for the quarter ending December 31, 2023, a +46.47% increase year-over-year.

Aldeyra Therapeutics Inc (ALDX) Earnings per Share 2024

ALDX earnings per share (TTM) was -$0.64 for the quarter ending December 31, 2023, a +39.62% growth year-over-year.

Aldeyra Therapeutics, Inc. engages in developing medicines for inflammatory diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase 2b clinical trial for the treatment of dry eye disease, as well as Phase 3 clinical trial for the treatment of noninfectious anterior uveitis. Its reproxalap is also in Phase 2b clinical trial for the treatment of allergic conjunctivitis, as well as Phase 2 clinical trial for the treatment of Sjögren-Larsson Syndrome. Its portfolio consists of ADX-1612, which inhibits heat shock protein 90 for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 and ADX-103. Aldeyra Therapeutics, Inc. has a partnership agreement with Janssen to develop other RASP scavengers for immune-mediated diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.